The adaption of the Next Generation Sequencing ( NGS ) technology to clinical laboratories has revolutionized the molecular diagnostics by reducing the costs and increasing the throughput. Clinical use of NGS enables simultaneous testing of multiple genes (gene panels), the entire exome or genome using a limited quantity of DNA, in addition to allowing for multiple patient samples to be tested in a single experiment.

Highly penetrant mutations in the cancer susceptibility genes,BRCA1andBRCA2, increase the risk of a person to develop Hereditary Breast and Ovarian Cancer (HBOC) to as high as 70-80%. The identification ofBRCAmutations is important for early cancer diagnostic, determination of therapeutic strategies, and individual and familial genetic counseling.

Currently, the most common approaches for clinical diagnostics of HBOC involve Sanger sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA) which detect sequence variants (point mutations) and copy-number variants (large deletions and duplications), respectively. This procedures, although very sensitive, is relatively expensive and requires a high amount of experimental workload and hands-on time. This abstract describes the clinical validation of an NGS-based gene panel forBRCA1/BRCA2testing that can detect both point mutations and copy-numberl alterations in a single assay.

The panel was designed to process 24 patient samples in a single assay, covers all 46 exonsBRCA1andBRCA2genes along with 20 nucleotides of intronic boundaries of each exon. The number of reads that align to every genomic region in NGS (Read Depth-RD) is proportional to the number of copies of that region present in the sample, therefore, this assay allows for parallel assessment of copy-number variants along with sequence changes in these genes, at a sensitivity of classical “gold-standard” approaches. Figure 1 shows the sequence alignment and RD for each nucleotide after bioinformatics normalization of the data inBRCA1andBRCA2genes for 24 patients. In this example, we demonstrate a detection of aBRCA1exon 24 deletion, and another complexBRCA2deletion involving exons 8-10 and 12-13 (Fig. 1A); as well, two cases ofBRCA1duplication involving exon 13 (Fig. 1B) in patients with hereditary breast cancer.

A total of 402 patients who had previously been tested with Sanger sequencing and MLPA, as well as 240 clinical patients without previous testing were included for the validation of the assay. 183 variants (point mutations and copy number variants) were detected. The NGS panel yielded 100% sensitivity (true positive rate) and 100% specificity (true negative rate) as compared to Sanger sequencing and MLPA in detectingBRCA1/BRCA2mutations. A high RD rate along with low intra and inter-sample coverage variability utilized in this approach allowed accurate estimation of copy number change.

We have expanded this approach which is currently in routine use in a clinical laboratory setting at the London Health Sciences Molecular Genetic Laboratory on many clinical gene panels, including Charcot Marie Tooth syndrome, hereditary cancer syndrome, epilepsy, dyslipidemia, mitochondrial genome sequencing and others, all of which meet or outperdorm the quality criteria of “gold standard” approaches, with significant cost, capacity, and throughput improvements.

Laila Cigana Schenkel, Erfan Aref Eshghi, Bekim Sadikovic
Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada
Molecular Genetics Laboratory, London Health Sciences Centre, London, ON, Canada

Publication

Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis.
Schenkel LC, Kerkhof J, Stuart A, Reilly J, Eng B, Woodside C, Levstik A, Howlett CJ, Rupar AC, Knoll JH, Ainsworth P, Waye JS, Sadikovic B
J Mol Diagn. 2016 Sep